ArticleProceedings of the National Academy of Sciences of the United States of America2021

Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.

Derek K Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.